UK biotechs win Biomedical Catalyst funding of almost £100m

Published: 20-Jun-2014
Research & Development Finance

Thirty-three UK companies have received business-led awards


UK biotechnology companies, including Autifony Therapeutics, Biosceptre UK, C4X Discovery, Mission Therapeutics and Oxford BioMedica, are among the 33 companies who have received business-led awards under the Biomedical Catalyst, analysis by the BioIndustry Association shows.

Almost £100m in business-led research by the Technology Strategy Board and approximately £70m in academic-led research by the Medical Research Council has been invested in the life sciences sector by the scheme. It has already leveraged a further £97m of private finance into the sector, with more to come.

The latest Biomedical Catalyst awards, announced by David Willetts MP, Minister for Science and Universities, represent a new £48m investment in biomedical research. They represent Round 4 early and late stage studies and Round 5 feasibility studies, as well as further Round 3 academic-led awards.

London-based Autifony Therapeutics will work with the University of Nottingham on a £2.2m project to progress a drug for tinnitus towards a Phase IIa clinical trial.

Biosceptre UK and Mission Therapeutics in Cambridge have each been awarded almost £150,000. Biosceptre for its work on novel therapeutic antibodies targeting cancer cell protein markers, and Mission Therapeutics to investigate the feasibility of the development of desumoylating enzyme inhibitors for the treatment of drug-resistant cancers.

Meanwhile C4X Discovery in Manchester will use just under £150,000 to investigate the feasibility of small molecules for the treatment of Type-2 diabetes and Oxford BioMedica will use its award of £2.2m to fund a Phase I/II trial of its 'once-only' gene therapy OXB-102 to treat individuals with Parkinson's disease from its Oxford headquarters.

Steve Bates, Chief Executive of the BIA, said: 'The Biomedical Catalyst is having a significant impact on the sector and the development of innovative new therapies for patients. Thanks to these awards combined with private capital, ground-breaking research in fields such as cancer therapeutics and illnesses such as Parkinson's disease and tinnitus is able to progress or accelerate more rapidly.'

  • Companies:
  • Oxford BioMedica
  • BioIndustry Association
  • Autifony Therapeutics
  • Biosceptre UK
  • C4X Discovery
  • Mission Therapeutics
See more

You may also like

Research & Development

Mission Therapeutics announces FDA approval for Phase II trial in acute kidney injury

Read more
Mission gains clearance from US FDA for Phase II trial of MTX562 after it receives official approval of its Investigational New Drug (IND) application

Trending Articles

  1. Lonza Capsules & Health Ingredients expands capsule manufacturing capacity in India and China New capsule manufacturing lines added at Lonza Capsules & Health Ingredients (CHI) facilities in Rewari (IN) and Suzhou (CN), highlighting the long-term strategic commitment to the business and the APAC region
  2. Novo Holdings completes acquisition of Catalent Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark
  3. ACG expands global footprint with new capsule manufacturing facility in Thailand New capsule manufacturing facility in Rayong, Thailand, is strategically positioned to serve key Asian markets
  4. Thermo Fisher Scientific reveals MagMax Sequential DNA/RNA Kit to advance blood cancer research The kit combines DNA and RNA isolation chemistries into a single kit, simplifying sample extraction for a broad range of downstream molecular applications
  5. Newcells Biotech raises additional funding from investors Newcells Biotech, a leading drug discovery partner specialising in the development of in vitro models and bespoke assay services to improve the prediction of in vivo human outcomes, has raised a further £1.2m from existing investors Mercia Ventures, Northstar Ventures and North East Finance

Upcoming event

EMPQ Essentials and Real-World Strategies for Successful Cleanroom Qualifications

16 January 2025 | Virtual See all

You may also like

Research & Development

Mission Therapeutics announces FDA approval for Phase II trial in acute kidney injury

Mission gains clearance from US FDA for Phase II trial of MTX562 after it receives official approval of its Investigational New Drug (IND) application
Research & Development

Mission paper outlines potential of experimental drug MTX325 as a disease-modifying therapy for Parkinson’s

The research was the result of collaborative work between Cambridge University, Harvard Medical School and Mission Therapeutics
Research & Development

C4XD receives first milestone payment of €3 million from Sanofi

€3 million milestone payment triggered by preclinical progression in oral IL-17A inhibitor programme
Finance

UK biotech raises $1.5bn in record quarter

The investment picture has been matched by rising share prices
Ingredients

Mission raises $15m and expands relationship with Pfizer

The new capital will support the development of Mission's deubiquitylating enzymes (DUB) platform, as well as growth of its pipeline of DUB inhibitor programmes
Research & Development

The power of national collaboration

To expedite the scale-up and production of a COVID-19 vaccine, the UK BioIndustry Association issued a call to arms to its members, reports Steve Bates, CEO
Research & Development

UK Government puts forward revised biopharma R&D tax credit cap

The UK BioIndustry Association has welcomed revised proposals to ensure genuine biotech companies are not penalised by a cap on R&D tax credits
Subscribe now